A detailed history of Alliancebernstein L.P. transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Alliancebernstein L.P. holds 22,020 shares of ADCT stock, worth $52,627. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,020
Previous 22,020 -0.0%
Holding current value
$52,627
Previous $69,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.55 - $5.09 $56,150 - $112,081
22,020 New
22,020 $69,000
Q4 2022

Feb 14, 2023

SELL
$2.87 - $5.24 $258,885 - $472,668
-90,204 Reduced 3.09%
2,824,956 $10.8 Million
Q3 2022

Nov 15, 2022

SELL
$4.66 - $10.31 $216,522 - $479,043
-46,464 Reduced 1.57%
2,915,160 $14.1 Million
Q2 2022

Aug 15, 2022

BUY
$5.96 - $14.99 $27,225 - $68,474
4,568 Added 0.15%
2,961,624 $23.5 Million
Q1 2022

May 13, 2022

BUY
$13.28 - $20.03 $1.98 Million - $2.99 Million
149,333 Added 5.32%
2,957,056 $43.4 Million
Q4 2021

Feb 14, 2022

BUY
$19.29 - $31.51 $2.96 Million - $4.84 Million
153,506 Added 5.78%
2,807,723 $56.7 Million
Q3 2021

Nov 10, 2021

SELL
$20.45 - $30.0 $8.16 Million - $12 Million
-399,031 Reduced 13.07%
2,654,217 $72.1 Million
Q2 2021

Jul 30, 2021

BUY
$20.38 - $27.04 $8.62 Million - $11.4 Million
422,757 Added 16.07%
3,053,248 $74.3 Million
Q1 2021

May 06, 2021

BUY
$22.75 - $34.05 $18.9 Million - $28.3 Million
829,755 Added 46.08%
2,630,491 $64.2 Million
Q4 2020

Feb 08, 2021

BUY
$25.26 - $38.02 $12.7 Million - $19.1 Million
502,171 Added 38.67%
1,800,736 $57.6 Million
Q3 2020

Nov 12, 2020

BUY
$32.87 - $51.05 $12.2 Million - $18.9 Million
370,988 Added 40.0%
1,298,565 $42.8 Million
Q2 2020

Aug 13, 2020

BUY
$29.65 - $46.81 $27.5 Million - $43.4 Million
927,577 New
927,577 $43.4 Million

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $186M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.